Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alkermes plc

Di cosa scriviamo

BiologiaFarmaceuticaMultimedialitàSaluteSanità

44 comunicati stampa

Guarda tutti i comunicati
21/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Psichiatria
Salute
Sanità
Farmaceutica
Biotecnologia
Alkermes to Report First Quarter Financial Results on May 5, 2026
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
16/04/2026
Eventi
Psichiatria
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
14/04/2026
Industria
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
01/04/2026
Industria
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
12/03/2026
Multimedialità
Industria
Assistenza all'Infanzia
Psichiatria
Salute
Sanità
Farmaceutica
Biotecnologia
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
10/03/2026
Eventi
Web e Social Network
Biotecnologia
Psichiatria
Salute
Farmaceutica
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
25/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
25/02/2026
Mercato del lavoro
Biotecnologia
Psichiatria
Salute
Farmaceutica
Alkermes plc Announces CEO Succession Plan
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
24/02/2026
Eventi
Web e Social Network
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
12/02/2026
Mercato azionario
Industria
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0